N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: Initial experience

Kohan, Andrés; Kolthammer, Jeffrey; Conejero, J.L. Vercher; Rubbert, Christian; Partovi, Sasan; Jones, Robert S.; Herrmann, Karin; Faulhaber, Peter

doi:10.1007/s00330-013-2914-y

Cited by 44 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PET/MR provided more accurate T staging of HN cancer than PET/CT and MRI (75,59, 50 %, respectively), but could not achieve statistical significance. N staging results also showed no significant difference between these modalities [31].…”

Section: Head and Neck Cancermentioning

confidence: 90%

See 1 more Smart Citation

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Kwon

Becker

Goo

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. 18F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

show abstract

Section: Head and Neck Cancermentioning

confidence: 90%

“…PET/MRI showed high diagnostic accuracy for lymph node metastasis of NSCLC when comparing with PET/CT (concordance rate of 91 %) [58]. Another study reported that diagnostic [59]. Diagnostic accuracy for intial staging was not significantly different in PET/ MR and PET/CT [60][61][62].…”

Section: Lung Cancermentioning

confidence: 94%

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Kwon

Becker

Goo

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…[602,728] In its very first stages of development, different information were obtained by using superparamagnetic iron oxide nanoparticles and 18F-Fluorodeoxyglucose as separate PET and MRI agents for imaging myocardial infraction in rats. [764] Since then, PET/ MRI dual imaging strategy have been clinically used for pancreatic and lung cancer [765] as well as human brain imaging [766] applications. Although MRI offers anatomic information with high spatial resolution, it mainly suffers from inability to provide functional and molecular information.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

192

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

“…Schwenzer et al (20) recently demonstrated the feasibility of simultaneous PET/ MRI for the assessment of pulmonary lesions showing a similar lesion characterization and tumor stage compared to that of FDG-PET/CT. Furthermore, Kohan et al (21) recently showed that FDG-PET/MRI is comparable to FDG-PET/CT for staging and quantitative assessment of mediastinal NSCLC lymph node metastases.…”

Section: Oncologymentioning

confidence: 99%

Clinical applications of PET/MRI: current status and future perspectives

Nensa

Beiderwellen²,

Heusch³

et al. 2014

Diagn Interv Radiol

110

View full text Add to dashboard Cite

Fully integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) scanners have been available for a few years. Since then, the number of scanner installations and published studies have been growing. While feasibility of integrated PET/MRI has been demonstrated for many clinical and preclinical imaging applications, now those applications where PET/MRI provides a clear benefit in comparison to the established reference standards need to be identified. The current data show that those particular applications demanding multiparametric imaging capabilities, high soft tissue contrast and/or lower radiation dose seem to benefit from this novel hybrid modality. Promising results have been obtained in whole-body cancer staging in non-small cell lung cancer and multiparametric tumor imaging. Furthermore, integrated PET/MRI appears to have added value in oncologic applications requiring high soft tissue contrast such as assessment of liver metastases of neuroendocrine tumors or prostate cancer imaging. Potential benefit of integrated PET/ MRI has also been demonstrated for cardiac (i.e., myocardial viability, cardiac sarcoidosis) and brain (i.e., glioma grading, Alzheimer's disease) imaging, where MRI is the predominant modality. The lower radiation dose compared to PET/computed tomography will be particularly valuable in the imaging of young patients with potentially curable diseases. However, further clinical studies and technical innovation on scanner hard-and software are needed. Also, agreements on adequate refunding of PET/MRI examinations need to be reached. Finally, the translation of new PET tracers from preclinical evaluation into clinical applications is expected to foster the entire field of hybrid PET imaging, including PET/MRI. B oth positron emission tomography (PET) and magnetic resonance imaging (MRI) are well-established imaging modalities that have been clinically available for more than 30 years. However, the combination of PET and computed tomography (CT) into PET/CT has heralded a new era of hybrid imaging driven by the rapid ascend of PET/CT and the decline of stand-alone PET. The integration of PET and CT into a hybrid system provided added value that exceeds the sum of its parts, in particular fast and accurate attenuation correction and the combination of anatomical and molecular information.Inspired by the vast success of PET/CT, the combination of PET and MRI was an obvious goal. Therefore initial solutions comprised the software based co-registration and post-hoc fusion (1) of independently acquired PET and MRI data, as well as shared tabletop sequential PET and MRI acquisition (2, 3). While the integration of PET and CT into a hybrid system was challenging but technically feasible, the integration of PET and MRI was considered extremely demanding, if not impossible. Two main technical challenges that had to be solved: in the first place development of a PET insert that is compatible to high magnetic field strengths normally used in MRI, and vice versa development ...

show abstract

N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: Initial experience

Abstract: •F18-FDG PET/MRI shows similar performance to F18-FDG PET/CT in lung cancer N staging. •PET/MRI has substantial interobserver agreement in N staging. •A three-segment model attenuation correction is reliable for assessing the mediastinum.

Cited by 44 publications

References 15 publications

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Clinical applications of PET/MRI: current status and future perspectives

Contact Info

Product

Resources

About